Você está no menu de acessibilidade

Utilize este identificador para citar ou criar um link para este item: http://acervodigital.unesp.br/handle/11449/1396
Registro de metadados completo
Campo DCValorIdioma
dc.contributor.authorPaccola, L.-
dc.contributor.authorCosta, R. A.-
dc.contributor.authorFolgosa, M. S.-
dc.contributor.authorBarbosa, J. C.-
dc.contributor.authorScott, I. U.-
dc.contributor.authorJorge, R.-
dc.date.accessioned2014-05-20T13:13:41Z-
dc.date.accessioned2016-10-25T16:34:31Z-
dc.date.available2014-05-20T13:13:41Z-
dc.date.available2016-10-25T16:34:31Z-
dc.date.issued2008-01-01-
dc.identifierhttp://dx.doi.org/10.1136/bjo.2007.129122-
dc.identifier.citationBritish Journal of Ophthalmology. London: B M J Publishing Group, v. 92, n. 1, p. 76-80, 2008.-
dc.identifier.issn0007-1161-
dc.identifier.urihttp://hdl.handle.net/11449/1396-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/1396-
dc.description.abstractBackground/aims: The aim of this study was to compare the morphological and visual acuity outcomes associated with a single intravitreal injection of triamcinolone acetonide versus bevacizumab for the treatment of refractory diffuse diabetic macular oedema.Methods: Twenty-eight patients were randomly assigned to receive a single intravitreal injection of either 4 mg/0.1 ml triamcinolone acetonide or 1.5 mg/0.06 ml bevacizumab. Comprehensive ophthalmic evaluation was performed at baseline and at weeks 1, 4, 8 (+/- 1), 12 (+/- 2) and 24 (+/- 2) after treatment. Main outcome measures included central macular thickness measured with optical coherence tomography (OCT) and best corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity.Results: Twenty-six patients (26 eyes) completed all study visits (two patients missed two consecutive study visits). Central macular thickness was significantly reduced in the intravitreal triamcinolone group compared with the bevacizumab group at weeks 4, 8, 12 and 24 (p<0.05). Logarithm of the minimum angle of resolution (LogMAR) best-corrected visual acuity was significantly higher at weeks 8 (0.69; similar to 20/100(+1)) and 12 (0.74; 20/100(-2)) in the intravitreal triamcinolone group compared with the bevacizumab group (weeks 8 (0.83; similar to 20/125(-1)) and 12 (0.86; 20/ 160(+2))) (p<0.05). Significant change from baseline in mean intraocular pressure (mmHg) was seen at week 4 (+2.25) only in the intravitreal triamcinolone group (p<0.0001). No patient had observed cataract progression during the study.Conclusions: One single intravitreal injection of triamcinolone may offer certain advantages over bevacizumab in the short-term management of refractory diabetic macular oedema, specifically with regard to changes in central macular thickness. The actual clinical relevance of our preliminary findings, however, remains to be determined in future larger studies.en
dc.format.extent76-80-
dc.language.isoeng-
dc.publisherB M J Publishing Group-
dc.sourceWeb of Science-
dc.titleIntravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)en
dc.typeoutro-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.contributor.institutionHosp Olhos Araraquara-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionPenn State Coll Med-
dc.description.affiliationUniv São Paulo, Dept Ophthalmol, Ribeirao Preto, SP, Brazil-
dc.description.affiliationHosp Olhos Araraquara, Macular Imaging & Treatment Div, UDAT, Araraquara, SP, Brazil-
dc.description.affiliationSão Paulo State Univ, Exact Sci Dept, Jaboticabal, SP, Brazil-
dc.description.affiliationPenn State Coll Med, Dept Ophthalmol & Publ Hlth Sci, Hershey, PA USA-
dc.description.affiliationUnespSão Paulo State Univ, Exact Sci Dept, Jaboticabal, SP, Brazil-
dc.identifier.doi10.1136/bjo.2007.129122-
dc.identifier.wosWOS:000252054700018-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofBritish Journal of Ophthalmology-
Aparece nas coleções:Artigos, TCCs, Teses e Dissertações da Unesp

Não há nenhum arquivo associado com este item.
 

Itens do Acervo digital da UNESP são protegidos por direitos autorais reservados a menos que seja expresso o contrário.